Adenocarcinoma of Unknown Primary, Adult Cholangiocarcinoma, Gallbladder Carcinoma, Gastric Adenocarcinoma, Malignant Gastrointestinal Neoplasm, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage IIIA Gallbladder Cancer, Stage IIIA Gastric Cancer, Stage III Ampulla of Vater Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Gastric Cancer, Stage III Pancreatic Cancer, Stage IV Ampulla of Vater Cancer, Stage IV Gallbladder Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer
Conditions
Brief summary
This phase I/II trial studies the side effects of genetic analysis-guided dosing of paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and irinotecan hydrochloride (FOLFIRABRAX) in treating patients with gastrointestinal cancer that has spread to other parts of the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Genetic analysis may help doctors determine what dose of irinotecan hydrochloride patients can tolerate.
Detailed description
PRIMARY OBJECTIVES: I. To determine the dose-limiting toxicity (DLT) rate in cycle #1 in each of three uridine diphosphate (UDP) glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) genotype groups (\*1/\*1, \*1/\*28, \*28/\*28) using genotype-guided dosing of irinotecan (irinotecan hydrochloride) as part of the FOLFIRABRAX regimen. SECONDARY OBJECTIVES: I. To determine the cumulative dose of each chemotherapy drug (nab-paclitaxel \[paclitaxel albumin-stabilized nanoparticle formulation\], irinotecan, 5-FU \[fluorouracil\]) administered in each genotype group. II. To determine the response rates (in patients with measurable disease) by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) for each different disease (pancreatic cancer, biliary tract cancer, esophageal/gastric cancer, adenocarcinoma of unknown primary) treated in the study. OUTLINE: Patients receive FOLFIRABRAX comprising paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV) over 0.5 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 1.5 hours, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
Interventions
DRUGPaclitaxel Albumin-Stabilized Nanoparticle Formulation
Given IV
DRUGLeucovorin Calcium
Given IV
DRUGIrinotecan Hydrochloride
Given IV
DRUGFluorouracil
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
University of Chicago
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma, gastric adenocarcinoma, cholangiocarcinoma, gall bladder adenocarcinoma, ampullary carcinoma, adenocarcinoma of unclear primary (with a gastrointestinal primary suspected), or other primary gastrointestinal malignancy for which the treating physician feels that FOLFIRABRAX is a reasonable therapeutic option * Patients with a history of obstructive jaundice due to the primary tumor must have a metal biliary stent in place * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 * Life expectancy \> 3 months * Absolute neutrophil count (ANC) \>= 1500/ul * Hemoglobin \> 9 g/dL * Platelets \> 100,000/ul * Total bilirubin =\< 1.25 times upper limit of normal * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 times upper limit of normal * Alkaline phosphatase =\< 2.5 times the upper limit of normal, unless bone metastasis is present in the absence of liver metastasis * Creatinine =\< 1.5 mg/dL * Measurable or non-measurable disease will be allowed, but only those with measurable disease will be evaluable for the response rate endpoint * Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment * Negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test at screening for patients of childbearing potential * Signed informed consent
Exclusion criteria
* Prior chemotherapy or radiation therapy for any cancer * Inflammatory bowel disease (Crohn's disease, ulcerative colitis) * Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version \[v.\] 4.0); pancreatic cancer patients with clinical evidence of pancreatic insufficiency must be taking pancreatic enzyme replacement * Neuropathy, grade 2 or greater by NCI-CTCAE, v. 4.0 * Documented brain metastases * Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment * Active uncontrolled bleeding * Pregnancy or breastfeeding * Major surgery within 4 weeks * Previous or concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the patient has been previously treated and the lifetime recurrence risk is less than 30% * Patients taking substrates, inhibitors and inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative drugs whenever possible * Patients with any polymorphism in UGT1A1 other than \*1 or \*28 (e.g., \*6) * History of interstitial lung disease, idiopathic pulmonary fibrosis, silicosis or connective tissue disorders * Subjects known to be human immunodeficiency virus (HIV)-positive, including those on combination antiretroviral therapy, are ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DLT rate in course 1 for each of the three genotype groups, graded according to NCI CTCAE v 4.0 | 4 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events graded according to NCI CTCAE v 4.0 | Up to 6 months | Adverse events will be summarized by type, grade, and attribution. |
| Response rates (by RECIST 1.1) for patients with each different type of gastrointestinal malignancy | Up to 6 months | These results will be compared descriptively to appropriate historical controls. Exact 90% confidence intervals will be generated for the response rates. |
| Cumulative doses of the drugs will be calculated as the sum of all doses received on protocol therapy for each patient | Up to 6 months | The means and standard deviations for patients in each genotype group will be reported. |
Countries
United States
Outcome results
None listed